Stem cell vesicles speed wound closure in aging fibroblasts but not young ones
Extracellular vesicles from anti-inflammatory polarized stem cells sped up in vitro wound closure in senescent human lung fibroblasts, with no effect on young cells.
Summary
Wound healing slows with age, partly because fibroblasts become senescent. Researchers tested whether extracellular vesicles (EVs) from human bone marrow mesenchymal stem cells (MSCs) could restore healing in cultured human pulmonary fibroblasts at different senescence stages. As cells progressed from young to deep senescence, scratch-style wound closure slowed in step with the share of senescence-marker-positive cells. Adding EVs from either naïve or anti-inflammatory polarized MSCs accelerated gap closure in senescent cultures but not in young ones. EVs from polarized MSCs worked better. Both EV types also lowered the percentage of senescent cells in senescent and deep senescent cultures. The authors suggest the benefit mainly reflects improved cell migration. These are cell-culture findings only, and they do not yet show benefit in living tissue or patients.
Detailed Summary
Wound healing gets slower with age, and the build-up of senescent cells is thought to be one reason. Fibroblasts drive wound repair, so restoring their function in aged tissue is an attractive goal for healthy longevity. Mesenchymal stem cells (MSCs) act mainly through paracrine signals, including extracellular vesicles (EVs). Whether MSC-derived EVs can help wound healing specifically in senescent cells had not been tested.
The team used primary human pulmonary fibroblasts aged by serial passaging into four stages: young (passage 15, doubling time about 1 day), pre-senescent (passage 40, about 1 week), senescent (passage 50, 2–3 weeks) and deep senescent (passage 60, no division). Stages were confirmed by growth slowing, morphology and senescence-associated β-galactosidase staining. EVs came from human bone marrow MSCs, either naïve (nMSC) or polarized toward an anti-inflammatory phenotype with PACAP-27 (pMSC). They were isolated by tangential flow filtration and sized mostly at 48–165 nm by nanoparticle tracking. Fibroblasts received 10^6 EVs per mL for 72 hours before a silicone-insert gap (wound) assay. Closure was tracked daily and summarized as area under the curve. Methods also described flow cytometry for cell cycle and cell death, and qRT-PCR for BCL2, cyclin D, p16, c-MET, HGF and vimentin.
Senescence markers rose steadily with passage, and wound closure slowed accordingly. Time to closure correlated strongly with the proportion of senescent cells (R = 0.925, p < 0.0001). The closure curve also changed shape, from a quadratic fit in young cultures to an exponential fit in senescent ones. The authors read this as a shift in the relative contributions of proliferation and migration. Both nMSC and pMSC EVs significantly accelerated gap closure in senescent cultures but not in young ones. pMSC EVs were more effective than nMSC EVs (p < 0.0001 in pre-senescent and senescent cultures). Both EV types reduced the percentage of senescent cells in senescent and deep senescent cultures. In pre-senescent cultures, pMSC EVs had no effect on senescent cell numbers, while nMSC EVs increased them. The abstract attributes the stronger effect of pMSC EVs mainly to cell migration.
The results suggest MSC EVs, especially from anti-inflammatory polarized MSCs, may selectively benefit aged or senescent cells and leave healthy young cells largely unchanged. That selectivity is attractive for a therapeutic. The pre-senescent result, where nMSC EVs raised senescent cell numbers, is a reminder that EV source and preparation matter.
The work was done in vitro in a single fibroblast type, using replicative senescence and a 2D gap assay. The provided text ended partway through the results, so the cell cycle, cell death and gene-expression findings and the mechanistic discussion could not be reviewed here. EV cargo was not described in the available text, and no in vivo data were reported.
Key Findings
- Wound closure slowed progressively from young to deep senescent fibroblasts, correlating strongly with senescent cell fraction (R = 0.925, p < 0.0001).
- Both naïve and polarized MSC-derived EVs accelerated in vitro wound closure in senescent fibroblasts but not in young cultures.
- EVs from anti-inflammatory polarized MSCs outperformed naïve MSC EVs for wound closure (p < 0.0001 in pre-senescent and senescent cells).
- Both EV types reduced the percentage of SA-β-gal-positive cells in senescent and deep senescent cultures.
- In pre-senescent cultures, naïve MSC EVs increased senescent cell numbers while polarized MSC EVs had no effect.
Methodology
In vitro study using primary human pulmonary fibroblasts aged by serial passaging into young, pre-senescent, senescent and deep senescent stages. Cells were pre-treated for 72 h with 10^6 EVs/mL from naïve or PACAP-27-polarized human bone marrow MSCs, then wound closure was measured with an Ibidi culture-insert gap assay. Data were analyzed by ANOVA and t-tests on area under the curve, with SA-β-gal staining, flow cytometry and qRT-PCR as supporting assays.
Study Limitations
Only one primary fibroblast type (lung) was studied in 2D culture, so generalization to skin or in vivo wounds is unproven. The gap assay cannot fully separate migration from proliferation, and the text available for review ended before the cell cycle, apoptosis and gene-expression results and discussion. Replicate numbers were modest (n ≥ 3 for wound assays), and EV cargo and mechanism were not characterized in the provided text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: